Skip to main content
. Author manuscript; available in PMC: 2023 Sep 6.
Published in final edited form as: ACS Chem Neurosci. 2021 Mar 31;12(8):1299–1312. doi: 10.1021/acschemneuro.0c00619

Figure 8. Screening for VSV-eGFP-SARS-CoV-2 inhibition.

Figure 8.

Compounds were screened at 25 μM for inhibition of VSV-eGFP-SARS-CoV-2 infection of Vero-E6-TMPRSS2 cells. Recombinant Spike S1 domain was included at 68 nM. Cells were infected for 36 h prior to live cell automated microscopy and quantification of sum GFP fluorescence intensity, normalized to cell count by HCS CellMask Blue, was measured and for each well and plotted with Prism 6. Results are presented as mean intensity ± SEM, # P <0.05 vs. mock; *P < 0.05 versus DMSO (n=3 replicates). Data was analyzed by a one-way analysis of variance (post hoc: Dunnett’s), *p<0.05.